HPV molecular assays: Defining analytical and clinical performance characteristics for cervical cytology specimens

Shen-Gunther, Jane; Yu, Xin

doi:10.1016/j.ygyno.2011.07.017

Cited by 23 publications

(41 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study revealed a similar percentage of HPV-DNA to studies performed in Slovenia and West Africa (Jenko et al, 2011;Piras et al, 2011). However, a higher percentage of HPV was observed in North Sardinia, Italy (35.9%); Madrid, Spain (43.2%); France (45.3%); Rio Grande do Norte, Brazil (48%); Kuwait (51%); and Texas, USA (63%) (Pannier-Stockman et al, 2008;Fernandes et al, 2009;Al-Awadhi et al, 2011;Martín et al, 2011;Piana et al, 2011;Shen-Gunther and Yu, 2011). In contrast, a lower percentage of infection was found in studies in Sweden (7%) and Albania (15.1%) (Naucler et al, 2009;Filipi et al, 2010).…”

Section: Discussionsupporting

confidence: 84%

Molecular analysis and conventional cytology: association between HPV and bacterial vaginosis in the cervical abnormalities of a Brazilian population

Peres¹,

Camarotti²,

Cartaxo³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We investigated the association between bacterial vaginosis (BV) and human papillomavirus (HPV) infection in Papanicolaou smears in a Brazilian population. Cross-sectional analysis was performed on 673 samples collected from women attending public health centers in Olinda (PE, Brazil) by conventional (2015) cytology methodology and molecular analysis, PCR tests (GP5+/6+ and MY09/11). Cytological abnormalities, BV, and HPV-DNA were detected in 23 (3.4%) samples, 189 samples (28.1%), and 210 samples (31.2%), respectively. GP5+/6+ primers resulted in higher detection performance than MY09/11 primers, with 81% concordance between both primers (P < 0.0001). The occurrence of HPV-DNA and BV had ORs of 8.59 (P < 0.0001) and 2.91 (P = 0.0089) for abnormal cytology, respectively, whereas the concomitant presence of both infections showed an OR equal to 3.82 (P = 0.0054). Therefore, we observed an association between abnormal cervical cytology and HPV infection, BV, or both HPV infection and BV. These results highlight the necessity of monitoring patients presenting not only HPV, but also BV, as risk factors for cervical lesion development.

show abstract

Section: Discussionsupporting

confidence: 84%

Molecular analysis and conventional cytology: association between HPV and bacterial vaginosis in the cervical abnormalities of a Brazilian population

Peres¹,

Camarotti²,

Cartaxo³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…In addition, HPV genotype prevalence based on a single set of consensus primers (MY09/MY11) may have been underestimated, since false negative results and biased amplification may occur, particularly in multiple HPV infections, as previously described. [32][33][34][35] Even with these limitations, the present study could provide a useful basis for improving clinical management of HIV infected women in respect to cervical cancer risk, due to the high correlation between multiple infection, low CD4 counts and the presence of cervical cytological abnormalities.…”

Section: Discussionmentioning

confidence: 98%

“…7 Briefly, 10 l of extracted DNA from each specimen was used in reaction mixtures containing 10 mM Tris-HCl, 50 mM, 2 mM MgCl 2 , all 4 deoxyribonucleotide triphosfates (each at 200 M), 2.5 U of Taq Gold DNA polymerase (Applied Biosystems, Forster City, CA), and 0.5 M of each primer. After DNA polymerase activation (15 min at 94 • C), 39 amplification cycles were carried out (95 • C for 50 s, 55 • C for 50 s, and 72 • C for 1 min), with a 10 min final extension at 72 • C. The analytical sensitivity, established on the basis of p-GEM plasmids containing a 450 bp L1 fragment of HPV16, 18,31,33,35,45,61,81, was 100 copies/reaction for HPV16, 18, 31, 61 81, and 150 copies/reaction for HPV33, 35, 45. HPV positive samples were typed by RFLP: 15 l of each unpurified PCR products were primarily digested with RsaI enzyme, which provides digestion patterns specific for a large number of genotypes. The first recognition of HPV genotype performed by RsaI was confirmed by further treatments with PstI, HaeIII, BamHI, Sau 3aI and HinfI restriction enzymes.…”

Section: Hpv-dna Detectionmentioning

confidence: 99%

“…This method uses biotinylated primers that amplify a 450-bp fragment within L1 region. Amplicons are detected by hybridisation in a low-density microarray containing triplicate DNA probes specific to 35 10 The declared analytical sensitivity ranges from 10 genome equivalents (HPV35, 39, 58, 66, 82) to 100 genome equivalents (HPV6, 11,16,18,26,31,33,45,51,52,53,59,69).…”

Section: Hpv-dna Detectionmentioning

confidence: 99%

See 1 more Smart Citation

Frequency and multiplicity of human papillomavirus infection in HIV-1 positive women in Italy

Garbuglia

Piselli

Lapa

et al. 2012

Journal of Clinical Virology

View full text Add to dashboard Cite

“…The clinical and cytological characteristics of the study population (N=90), as well as, HPV DNA sequencing results have been published [16]. To recap our methods, genomic DNA was extracted from cervicovaginal cells and tested for HPV DNA by PCR using 3 primer sets, i.e.…”

Section: Methodsmentioning

confidence: 99%

Genotyping human papillomaviruses: Development and evaluation of a comprehensive DNA microarray

Shen-Gunther

Rebeles²

2013

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

Goals To define the analytical and clinical performance of a human papillomavirus (HPV) custom-designed microarray targeting the HPV L1 gene for viral genotyping. Methods Microarray probes were designed by cataloging the genome sequence of all 120 known HPV types to generate tiling probes using eArray® software against the unique L1 capsid gene segments targeted by MY09/11 and FAP59/64 primers. The microarray (1 slide×8 arrays×60 K features) synthesized in situ by inkjet printing was tested using synthetic type-specific HPV DNA and existing HPV DNA from cervical cytology. The synthetic HPV L1 segments (genotypes 6, 11, 16, 18, 31, 33, 35, 45, 53, 58, 66, 73, 83) were manufactured from sequences stored in the NCBI taxonomy database. Using the hybridization patterns of the synthetic HPV DNA as the Support Vector Machine classifier, HPV DNA from patient samples were genotyped and compared to antecedent DNA sequencing/BLAST® results for concordance. Results 16 cytology-derived HPV DNA samples and 13 synthetic type-specific HPV DNA samples were tested singly, in duplicate, or in combination on 40 arrays. The synthetic HPV DNA hybridization patterns were found to be uniquely distinctive to serve well as a classifier of unknown HPV-containing specimens. For the 16 HPV DNA+ samples classified, 15 were concordant with DNA sequencing results. In 6/16 (38%) samples, the microarray hybridization pattern revealed ≥2 concurrent HPV infections. Conclusion The novel “HPV Array” was sensitive and specific for detecting single and multiple infections. This proof-of-principle project demonstrated the accuracy and advantages of microarray technology for HPV genotyping.

show abstract

HPV molecular assays: Defining analytical and clinical performance characteristics for cervical cytology specimens

Cited by 23 publications

References 28 publications

Molecular analysis and conventional cytology: association between HPV and bacterial vaginosis in the cervical abnormalities of a Brazilian population

Molecular analysis and conventional cytology: association between HPV and bacterial vaginosis in the cervical abnormalities of a Brazilian population

Frequency and multiplicity of human papillomavirus infection in HIV-1 positive women in Italy

Genotyping human papillomaviruses: Development and evaluation of a comprehensive DNA microarray

Contact Info

Product

Resources

About